557 related articles for article (PubMed ID: 25886910)
1. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
2. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
3. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.
Asmar F; Punj V; Christensen J; Pedersen MT; Pedersen A; Nielsen AB; Hother C; Ralfkiaer U; Brown P; Ralfkiaer E; Helin K; Grønbæk K
Haematologica; 2013 Dec; 98(12):1912-20. PubMed ID: 23831920
[TBL] [Abstract][Full Text] [Related]
5. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
6. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
8. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
9. TET2 coactivates gene expression through demethylation of enhancers.
Wang L; Ozark PA; Smith ER; Zhao Z; Marshall SA; Rendleman EJ; Piunti A; Ryan C; Whelan AL; Helmin KA; Morgan MA; Zou L; Singer BD; Shilatifard A
Sci Adv; 2018 Nov; 4(11):eaau6986. PubMed ID: 30417100
[TBL] [Abstract][Full Text] [Related]
10. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
Rasmussen KD; Berest I; Keβler S; Nishimura K; Simón-Carrasco L; Vassiliou GS; Pedersen MT; Christensen J; Zaugg JB; Helin K
Genome Res; 2019 Apr; 29(4):564-575. PubMed ID: 30796038
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
12. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis.
Tulstrup M; Soerensen M; Hansen JW; Gillberg L; Needhamsen M; Kaastrup K; Helin K; Christensen K; Weischenfeldt J; Grønbæk K
Nat Commun; 2021 Oct; 12(1):6061. PubMed ID: 34663818
[TBL] [Abstract][Full Text] [Related]
13. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation.
Hon GC; Song CX; Du T; Jin F; Selvaraj S; Lee AY; Yen CA; Ye Z; Mao SQ; Wang BA; Kuan S; Edsall LE; Zhao BS; Xu GL; He C; Ren B
Mol Cell; 2014 Oct; 56(2):286-297. PubMed ID: 25263596
[TBL] [Abstract][Full Text] [Related]
14. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
Bahari G; Hashemi M; Naderi M; Taheri M
Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
[TBL] [Abstract][Full Text] [Related]
15. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
[TBL] [Abstract][Full Text] [Related]
16. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
17. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
18. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX.
Ko M; An J; Bandukwala HS; Chavez L; Aijö T; Pastor WA; Segal MF; Li H; Koh KP; Lähdesmäki H; Hogan PG; Aravind L; Rao A
Nature; 2013 May; 497(7447):122-6. PubMed ID: 23563267
[TBL] [Abstract][Full Text] [Related]
19. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
20. Tracking hematopoietic precursor division ex vivo in real time.
Wang Y; Tian H; Cai W; Lian Z; Bhavanasi D; Wu C; Sato T; Kurokawa M; Wu D; Fu L; Wang H; Shen H; Liang D; Huang J
Stem Cell Res Ther; 2018 Jan; 9(1):16. PubMed ID: 29361987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
